Background multifactorial intervention is unable to improve endothelial dysfunction/cardiovascular outcome in type 2 diabetes. Intensive insulin therapy improves pancreatic β-cell dysfunction in patients with early stage diabetes. We investigated the effect of intensive insulin therapy on endothelial dysfunction in these patients.
Methods
One hundred and sixteen patients with newly diagnosed type 2 diabetes and 59 healthy subjects received flow-mediated dilatation (Fmd) and von Willebrand factor (vWF) measurement. diabetic patients were further treated with either multifactorial intervention (group A), or intensive insulin therapy (group b) for 2 weeks. both Fmd and vWF measurement were repeated at the same time. Fmd was reassessed 90 days after intervention. results compared with healthy subjects, Fmd in diabetic patients was significantly lower (group A: 15.99 ± 7.81 % vs. 25.17 ± 7.12 %, P < 0.01; group b: 16.85 ± 7.30 % vs. 25.17 ± 7.12%, P < 0.01), plasma vWF was significantly higher (group A: 224.34 ± 7.36 U/l vs. 109.69 ± 6.30 U/l, P < 0.01; group b: 219.18 ± 6.92 U/l vs. 109.69 ± 6.30 U/l, P < 0.01). After treatment, there was no significant change of Fmd in either group. The vWF did not change after multifactorial intervention (220.96 ± 6.85 U/l vs. 224.34 ± 7.36 U/l, P = 0.49), but significantly decreased after intensive insulin therapy (155.08 ± 11.82 U/l vs. 219.18 ± 6.92 U/l, P = 0.0013).
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Methods
Patients. From April 2009 to December 2009, patients with newly diagnosed type 2 diabetes were referred from general practitioners in 12 medical centers inside Guangdong Province of China, to Comprehensive Diabetes Center of Sun Yat-sen University Memorial Hospital. The diagnostic criteria were strictly based on recommendations of the American Diabetes Association. 13 Exclusion criteria were: type I or other types of diabetes; combined with ketosis, ketoacidosis, hyperosmolar coma or severe stress state within the past 6 months; complicated with cardiovascular diseases (a history of physician-diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack or who had undergone an invasive cardiovascular procedure); complicated with diabetic nephropathy or diabetic retinopathy; hypertension (defined as higher than 140/90 mm Hg, or taking medication prescribed for hypertension); serious liver and kidney dysfunction; pregnancy or breast-feeding women. One hundred and twenty six patients were initially enrolled. Ten patients (all from the group A, treated with multifactorial intervention therapy, see "Study design" section) declined to continue postintervention visits and dropped from the final analysis. Thus, 116 patients completed the entire study. At the beginning of the study, 59 age-matched healthy subjects were also enrolled in this study. The baseline characteristics of patient groups are shown in Table 1 .
Study design. Both healthy subjects and diabetic patients received FMD and plasma vWF measurement at the beginning of the study. Only diabetic patients participated in subsequent randomized prospective intervention study. Before the intervention began, they were randomly allocated into two groups (according to the table of random numbers): group A and B. In group A, the patients were treated with multifactorial intervention therapy with hypoglycemic, antihypertensive, and lipid-lowering agent. In group B, the patients were treated with early intensive insulin therapy ( Table 1 and Figure 1) . During follow-up, occurrence of any cardiovascular disease (physiciandiagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack or underwent an invasive cardiovascular procedure) meant the termination of this study. The study was sponsored by National Natural Science Foundation of China (No. 30973480) and the Science & Technology Program of Guangdong Province (No. 2009B060700104). No pharmaceutical company had role in the design of the study, the accrual or analysis of the data, or the preparation of the manuscript. All authors vouch for the accuracy and completeness of the data and the analysis. The protocol was approved by the institutional review board at each of the 12 participating centers and the ethics committee of the Sun Yat-sen University. All patients gave written informed consent to the study. An independent data and safety monitoring committee monitored safety and efficacy.
Treatment protocol and therapeutic goals. In group A, the protocol of multifactorial intervention therapy was described in our previous publication. 8 Briefly, patients with a body mass index of 27 or more were started on two oral agents, metformin plus rosiglitazone; those with a body mass index of <27 were started on glimepiride plus rosiglitazone. All agents were started on half the maximal doses. Subsequently the dosages were adjusted to meet the goal of glycated hemoglobin levels <7.0%. Antihypertensive and lipid-lowering medication and dosages were determined according to protocol guidelines. 8 The goal of blood pressure control is lower than 130/80 mm Hg. The goal of lipid control is based on recommendations of the American Diabetes Association. 14 Dietary, exercise, and diabetes education were provided to all patients following the original contributions
Endothelial Function in Diabetes After Insulin Therapy
recommendations from the American Diabetes Association. 14 All patients were prescribed aspirin unless contraindicated. In group B, the intensive insulin therapy protocol strictly followed the published recommendations. 11, 12 Briefly, the basal and premeal insulin doses were adjusted according to the preprandial and postprandial blood glucose levels. After 2-week treatment, preprandial blood glucose level returned to 79-108 mg/dl and postprandial blood glucose level returned to 80-124 mg/dl. After 2 weeks, the continuous treatment was the same as that in group A.
Clinic visits. Patients visited clinic 14 days after treatment, then monthly for the first 3 months, and then every 3 months or more frequently if required per glucose control criteria. 8 Body weight, blood pressure, fasting glucose, lipids, and other biochemical index were measured during the visits, and therapy was adjusted if necessary. Home blood glucose and hypoglycemic symptoms was monitored and recorded. Any possible side effects from all therapeutic agents were also monitored and recorded.
Plasma vWF measurement. Two ml of venous blood sample was drawn from venous blood vessel. Plasma vWF was measured by 2-step double-antibody sandwich enzyme-linked immunosorbent assay strictly following the published instruction. 15 The measurement in each patient was repeated 2 weeks after the treatment in both group A and B. We were unable to perform plasma vWF measurement after 90-day treatment because most of patients were unwilling to receive new peripheral blood vessel access for sample collection.
Assessment of brachial artery FMD and endotheliumindependent dilatation.
The protocol for the assessment of FMD and endothelium-independent dilatation (EID) was described in the previously published work. 8 Briefly, vascular ultrasound scans were performed in the morning, in a quiet room temperature from 22 °C to 26 °C. Patients remained resting in a recumbent position 10 min before the investigation and throughout the whole scan sequence. A B-mode scan of the right brachial artery was obtained in longitudinal section between 5 and 10 cm above the elbow, using a 9-MHz linear array transducer and a standard LOGIQ 9 ultrasonography system (GE Biomedica, Waukesha, WI). Transducer positioning and ultrasound settings were adjusted to optimize the definition of anterior and posterior media-intima interfaces that demarcated the brachial artery diameter. This diameter was calculated as the average of measurements made using an electronic caliper during three cardiac cycles at end-diastole. The brachial artery diameter was measured at a fixed distance from an anatomical marker, such as a bifurcation, and the position of the transducer was marked on body surface to ensure that the same part of the artery was assessed on the same set of visit. Reactive hyperemia (the endotheliumdependent stimulus) was induced by transient upper arm flow occlusion (280 mm Hg, 5 min) by a blood pressure cuff wrapped around the upper arm. FMD was calculated as the percentage changes from the resting artery diameter in response to reactive hyperemia ~90-120 s after cuff deflation. After a 20-min vascular recovery period, a repeat baseline scan was acquired, after which nitroglycerin (tablet, 0.5 mg) was administered sublingually. Five minutes later, the artery was rescanned. EID was calculated as the diameter increase (in percent) in response to nitroglycerin compared to the second baseline scan. Vascular reactivity was respectively assessed before intervention, 14 days and 90 days after intervention, with a randomized, singleblind, and parallel method. All FMD and EID measurements were performed by the same ultrasonographist (Y.W.) to avoid Basic characteristics of healthy subjects and diabetic patients are shown in Table 1 .
Compared with the average FMD value in age-matched healthy subjects, the average FMD value in patients with newly diagnosed type 2 diabetes was significantly lower ( Table 2) . Also, compared with the average vWF level in age-matched healthy subjects, the average vWF level in patients with newly diagnosed type 2 diabetes was significantly higher ( Table 2) . These results confirmed our previous findings, that significant vascular endothelial dysfunction/injury already exists in patients with newly diagnosed type 2 diabetes. 8 In group A, after 14-day treatment with multifactorial intervention therapy, only fasting blood glucose and low-density lipoprotein level decreased significantly. However, in group B, after 14-day intensive insulin therapy, fasting blood glucose, total cholesterol, triglyceride and low-density lipoprotein levels all significantly decreased ( Table 1) .
After both 14-day and 90-day treatment, there was no significant change in average FMD values ( Table 2 and Figure 2 ), compared with their baseline values in either group A or group B. The average vWF level ( Table 2 and Figure 3 ) in group A did not change significantly after multifactorial intervention therapy. However, the average vWF level in group A decreased significantly after intensive insulin intervention therapy. discussion Clinically, type 2 diabetes is usually not diagnosed until fasting glucose becomes abnormal. In prediabetic states, insulin resistance, subclinical hyperglycemia and other diabetes-associated Data are described as mean ± s.d. No significant difference in FMD between group A and B: P = 0.22 (before treatment); P = 0.24 (after 14-day treatment); P = 0.32 (after 90-day treatment).
-, We were unable to perform plasma vWF measurement after 90-day treatment because most of patients were unwilling to receive new peripheral blood vessel access for sample collection. EID, endothelium-independent dilatation; FMD, flow-mediated dilatation; vWF, von Willebrand factor. *P < 0.01, diabetes group vs. healthy subject group; **P = 0.0013, vWF (group B, after 14-day treatment) vs. (group B, before treatment); ***P = 0.0020, vWF (group B, after 14-day treatment) vs. (group A, after 14 days treatment). original contributions decreased progression of vascular intima-media thickness was first observed 6 years after the end of the trial. Our previous study also found that, even though in newly diagnosed, normotensive type 2 diabetic patients, the improvement of preexisting vascular endothelial dysfunction did not occur until 5 years after multifactorial intervention therapy. 8 It is worth noting that, in current clinical practice, the medication potentially improving vascular endothelial function, including insulin sensitizer, angiotensin-converting enzyme-inhibitors, antilipid agents, and so on, are usually not started until the relative late and advanced stages of diabetes. As the result, the reverse of endothelial dysfunction is even more difficult and could take longer time to become clinically detectable. A novel clinical therapy strategy, intensive insulin therapy, was recently suggested in patients with newly diagnosed type 2 diabetes. 9, 10 Several prospective clinical trials demonstrated that it could effectively improve pre-existing pancreatic β-cell dysfunction, and potentially achieve the goal to completely normalize blood glucose. 11, 12 In the present study, using FMD measurements, we were unable to detect significant improvement of vascular endothelial dysfunction in patients with newly diagnosed type 2 diabetes in short time after intensive insulin therapy. However, their plasma endothelium-derived marker, vWF, significantly decreased after receiving 2-week insulin therapy. When compared with the plasma levels in patients receiving standard multiple factorial intervention therapy, the plasma levels of vWF in patients receiving intensive insulin therapy were significantly lower.
Atherosclerotic lesions usually arise at sites of endothelial dysfunction/damage, which initiates an endothelial cell proliferative and inflammatory response. Subsequent recruitment of monocytes into the subendothelial space is followed by their uptake of low-density lipoprotein-derived cholesterol and differentiation into foam cells. 18 In diabetes, hyperglycemia and other metabolic problems cause the formation of advanced glycation end products, activation of protein kinase C isoforms, and increased hexosamine pathway flux, 19 all of which contribute to increased oxidative stress and endothelial dysfunction/injury. 20 Thus, severe and diffuse atherosclerotic lesions throughout the arterial trees are often found by diagnostic coronary angiogram. Due to the unique localization of endothelium (continuously exposed to blood circulation and various inflammatory cells), the endothelium-derived biomarkers released into blood could potentially reflect early stage endothelial dysfunction/injury. Even though multiple candidate markers are under intensive investigation, such as endothelium-derived microparticle 21 and endothelial progenitor cells, 22 plasma vWF level is by far mostly well accepted one for vascular endothelial dysfunction measurement. vWF is a large glycoprotein produced by vascular endothelial cells that mediates platelet adhesion to injured endothelium, and will be released to plasma when the endothelial cells are damaged. It is well established that high plasma vWF levels are associated with an increased risk of myocardial infarction and ischemic stroke. 23, 24 Meanwhile, it is under intensive investigation if vWF is causally related to the occurrence of arterial thrombosis, or is primarily just a marker of endothelial dysfunction/ injury, which predisposes to atherosclerosis and subsequent arterial thrombosis. 25, 26 Both plasma vWF level and FMD measurement have been also closely associated with insulin resistance and type 2 diabetes mellitus. 27, 28 Thus, studies of plasma vWF level may potentially help early identification, stratification, and follow-up on the therapeutic efficacy of vascular endothelial dysfunction in type 2 diabetic patients.
Early intensive insulin therapy has been recognized and rapidly developed in recent years. Other than its effect on improvement of pancreatic β-cell function, its potential effect on other cell types in diabetic patients are largely unknown, but under intensive investigation. The evidence from basic research is mounting that insulin upregulates the transcription of endothelial nitric oxide syntheses gene, and increase endothelial nitric oxide production via the activation of PI 3-kinase and protein kinase B. [29] [30] [31] Early introduction of insulin therapy in diabetic patients, not only maintains pancreatic β-cell housekeep function, but also helps endothelial cell to minimize derangements in normal host defense mechanisms and modulate release of inflammatory mediators, thus reverse early endothelial dysfunction and improve long-term vascular complications in type 2 diabetes. 32,33 UK Prospective Diabetes Study (UKPDS) group reported that patients with early stage type 2 diabetes who received intensive insulin therapy had a lower incidence of microvascular diseases in a long-term, compared with those without intensive insulin therapy. 34 Our present study is the first prospective clinical study, to our knowledge, providing the evidences showing that early intensive insulin therapy could significantly reduce endothelial injury in newly diagnosed type 2 diabetes patients. Thus, compared with the effect from traditional and standard multiple factorial intervention therapy, 8 the improvement of endothelial injury/dysfunction caused by early intensive insulin therapy, will likely occur earlier, and more remarkable.
As well known, even with current aggressive multifactorial risk management, including tight lipid, blood pressure, and glucose control, significant residual cardiovascular risk is present in diabetic patients. Actually, there was still a 19% cardiovascular disease event rate over 5 years (compared with 32% in the conventionally treated group). Unfortunately, the individual risk reduction achieved by each drug group does not add up. Thus, even though multiple novel pharmaceutical agents are currently under development, which target on novel molecular mechanisms causing vascular endothelial dysfunction, early identifying and treating fundamental process involved in the development of macro-and microvascular diseases (e.g., pancreatic β cell and endothelial cell dysfunction) more likely further reduce this residual cardiac risk in diabetic patients.
Most of current clinical outcome studies used retinopathy or nephropathy to measure diabetic microvascular complications, 35 However, for detecting early stage endothelial cell dysfunction and monitoring its change after various clinical therapies, it is still a specific, but not sensitive method. Instead, the biomarker of endothelial dysfunction/injury could be a better candidate for this application. Thus, our current study not only provided information leading to the better understanding of the effect of early intensive insulin therapy on the long-term macro-and microvascular diseases in type 2 diabetic patients, but also advocated the application of a novel noninvasive method to identify, stratify and monitor vascular endothelial dysfunction in early disease stage.
study limitations
We measured plasma vWF level and FMD in diabetic patients at the beginning of the study and compared with those in agematched healthy subjects. Taking into account of the known significant cardiovascular risk on patient's health, we did not set up a complete placebo control group in diabetic patients during the following intervention study. However, the study conclusion is strengthened by the date from the comparison between two therapeutic groups treated with either early intensive insulin therapy or multifactorial intervention therapy. Each subject was also used as his/her own control after different therapy courses. Due to the cost of FMD, the numbers of both healthy and diabetic subjects included in this study are relative small. Thus, even though the average FMD value in group B slightly improved after 2-week intensive insulin therapy, and was higher than the one in group A, the differences were not statistically significant. One of the possible reasons could be the limited patient number. Finally, whether patients' long-term clinical outcomes, including macro-and microvascular events in therapeutic groups with either early intensive insulin therapy or multifactorial intervention therapy are correlated with their vWF and FMD measurement is still under the further investigation.
